|
Notification of cessation of securities - GTG
|
10 May 2023 at 2:20pm
|
|
Updated Investor Presentation and Investor Webinar
|
2 May 2023 at 9:25am
|
|
Publication Validates geneType for Melanoma Risk Assessment
|
28 April 2023 at 9:25am
|
|
Appendix 4C & Quarterly Activities Report - March 2023
|
27 April 2023 at 9:25am
|
|
Change in substantial holding
|
24 April 2023 at 8:35am
|
|
Publication Validates geneType Prostate Cancer Risk Test
|
19 April 2023 at 9:45am
|
|
GeneType MultiTest Panel Expanded Inclusion of New Diseases
|
27 March 2023 at 10:15am
|
|
Response to ASX Query
|
17 March 2023 at 9:59am
|
|
Further Study Validates geneType Breast Cancer Risk Test
|
13 March 2023 at 9:50am
|
|
Notification of cessation of securities - GTG
|
7 March 2023 at 12:20pm
|
|
Change in substantial holding
|
1 March 2023 at 8:40am
|
|
Half Year Financial Results Investor Webinar Presentation
|
28 February 2023 at 8:40am
|
|
Appendix 4D & Half-year Financial Report December 2022
|
27 February 2023 at 9:25am
|
|
2023 Half-year Financial Results Investor Webinar
|
24 February 2023 at 9:15am
|
|
Notification of cessation of securities - GTG
|
17 February 2023 at 12:59pm
|
|
Receipt of R&D Tax Incentive Refund for geneType Multi Test
|
17 February 2023 at 10:10am
|
|
Publication Highlights geneType Outperforms Current Models
|
9 February 2023 at 9:35am
|
|
Business Update - February 2023
|
9 February 2023 at 9:30am
|
|
Change in substantial holding
|
9 February 2023 at 8:40am
|
|
Prospectus Supplement
|
8 February 2023 at 10:59am
|
|
GTG Announces Closing of US$5M Registered Direct Offering
|
8 February 2023 at 10:25am
|
|
Section 708A - Cleansing Notice
|
7 February 2023 at 4:40pm
|
|
Application for quotation of securities - GTG
|
7 February 2023 at 4:30pm
|
|
Proposed issue of securities - GTG
|
7 February 2023 at 3:40pm
|
|
Supplementary Announcement - Comprehensive Risk Test
|
6 February 2023 at 11:05am
|
|
Proposed issue of securities - GTG
|
6 February 2023 at 10:10am
|
|
Genetic Technologies Announces US$5M Registered Direct Offer
|
6 February 2023 at 10:10am
|
|
World First Comprehensive Risk Test-Breast & Ovarian Cancer
|
3 February 2023 at 10:10am
|
|
Appendix 3Y Change of Directors Interest Notice
|
2 February 2023 at 4:45pm
|
|
GTG to form Strategic Alliance with global leader QIAGEN
|
1 February 2023 at 10:20am
|
|
Appendix 4C and Quarterly Business Update December 2022
|
30 January 2023 at 2:40pm
|
|
Colorectal Cancer Model Presented at ASCOGI Cancer Symposium
|
24 January 2023 at 3:00pm
|
|
Notification of cessation of securities - GTG
|
11 January 2023 at 11:25am
|
|
Appendix 3Y - Lindsay Wakefield
|
11 January 2023 at 9:55am
|
|
Change in substantial holding
|
7 December 2022 at 8:45am
|
|
GeneType Published in PLUS ONE for CVD & Type 2 Diabetes
|
6 December 2022 at 10:15am
|
|
Results of AGM
|
28 November 2022 at 2:10pm
|
|
AGM Presentation and Chairman's Address
|
28 November 2022 at 10:15am
|
|
GTG Webinar on Risk Assessment Tests for Serious Disease
|
10 November 2022 at 12:45pm
|
|
Notification of cessation of securities - GTG
|
9 November 2022 at 4:25pm
|
|
Genetype for Ovarian Cancer published in European Journal
|
9 November 2022 at 2:30pm
|
|
Change of Director's Interest Notice
|
9 November 2022 at 12:55pm
|
|
Genetic Technologies Investor Presentation Webinar
|
4 November 2022 at 10:30am
|
|
Notice of Annual General Meeting/Proxy Form
|
27 October 2022 at 3:30pm
|
|
Genetic Technologies AusBioInvest Presentation
|
27 October 2022 at 11:05am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
25 October 2022 at 10:10am
|
|
Bloomberg Airs Genetic Technologies Business Update
|
14 October 2022 at 10:35am
|
|
Appointment of CFO and Company Secretary
|
10 October 2022 at 9:25am
|
|
GeneType Outperforms Traditional Risk Assessments
|
29 September 2022 at 8:30am
|
|
Change in substantial holding
|
14 September 2022 at 8:30am
|
Genetic Technologies